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http:WHAT THIS PAPER ADDS
This paper offers a specific analysis of thoracic aortic endovascular repair (TEVAR) for type B acute aortic
dissection complicated by descending thoracic aneurysm present on admission after the clinical onset of the
dissection. This condition has not been specifically analysed in previous cohorts.Objectives: To analyse the results and review the literature about thoracic aortic endovascular repair (TEVAR) for
type B acute aortic dissection (TBAAD) complicated by descending thoracic aortic aneurysm (DTA) in the
hyperacute or acute phases.
Methods: This was a multicentre, observational descriptive study. Inclusion criteria were TBAAD with a DTA of
50 mm, TBAAD on an already known aneurysmal descending thoracic aorta, and TBAAD presenting with an
enlarged aorta with a total diameter <50 mm, but with >50% diameter increase compared with a previous
computed tomography angiography (CTA) showing a non-dissected aorta with normal sizing. Primary endpoints
were early and long-term survival, freedom from TEVAR and aortic related mortality (ARM), and freedom from
re-intervention.
Results: Twenty-two patients were included in the analysis. The mean aortic diameter was 66  26 mm (range
42e130; IQR 51e64). The in hospital TEVAR related mortality was 14% (n ¼ 3). The mean radiological follow-up
was 56  45 months (range 6e149; IQR 12e82), and the follow-up index 0.97  0.1. All surviving patients were
available for follow-up. During follow-up the cumulative mortality was 26% (n ¼ 5) and TEVAR related mortality
was 5% (n ¼ 1). Overall the estimate of survival was 82% (95%CI: 61.5e93) at 1 year, and 64% at 5 years. Ongoing
primary clinical success was 79% (re-intervention n ¼ 4). Freedom from aortic related mortality was 86% (95%CI:
66e95) at 1 and 5 year, while freedom from re-intervention was 95% (95%CI: 75.5e95) at 1 year, and 77% (95%
CI: 50e92) at 5 years.
Conclusions: In our experience, DTA is a frequent complication from the very beginning of the clinical onset of
TBAAD. In this high-risk cohort, TEVAR showed satisfactory results, better than those predicted by the risk score
for open repair, with favourable stability of the aortic diameter and no aortic related adverse events during
follow-up.
 2017 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Complicated type B acute aortic dissection (TBAAD)
currently identifies cases with persistent symptoms despite
the best medical treatment, impending or frank rupture, or
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//dx.doi.org/10.1016/j.ejvs.2017.02.022descending thoracic aneurysm (DTA) has been made rarely
in acute onset of the dissection, since they are more
frequently seen in the chronic phase as a degeneration of
an uncomplicated TBAAD.2 In such an acute setting,
thoracic aortic endovascular repair (TEVAR) has been sug-
gested to bring potential advantages over open repair (OR),
while concerns remain in the long-term period because of
aortic-related events such as rupture or re-interventions of
the untreated residual dissection.3,4 The most recent pub-
lished experiences analysed mainly chronic dissection
related aneurysmal degeneration of the descending
thoracic aorta.5e17 The aim of this paper was to analyse our
Figure 1. Acute type B aortic dissection complicated by descending aneurysm. Aneurysm involved the entire descending aorta (AeC),
whereas the dissecting flap extended downstream to the abdominal aorta (D).
794 G. Piffaretti et al.results of a consecutive cohort of patients treated by TEVAR
for TBAAD complicated by the presence of DTA in the hy-
peracute or acute phase.
MATERIALS AND METHODS
Patient cohort
Since November 2000, all TBAADs were identified from a
computerized database registry, which, at each centre,
remained consistent over the study period. Information
about demographics, comorbidities, medical and surgical
history, operative details and post-operative events duringthe hospital stay, and follow-up were all registered. This was
a multicentre, observational descriptive study with retro-
spective analysis of consecutive patients treated by TEVAR
for TBAAD complicated by DTA in the hyperacute or acute
phases. This experience includes patients observed from
September 2001 to December 2014; for the final analysis,
the end of the study was December 31, 2014.
Inclusion criteria were as follows:
 TBAAD with DTA of 50 mm (Fig. 1AeD)
 TBAAD upon an already known aneurysmal descending
thoracic aorta (Fig. 2A, B)
Figure 2. Acute dissection on an already aneurysmal descending thoracic aorta: the aneurysm involved the entire descending aorta starting
just beyond the origin of the left subclavian artery (A), and the dissecting flap developed in the middle third of the descending thoracic
aorta (B).
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diameter <50 mm, which, however, had >50%
diameter increase compared with a previous computed
tomography angiogram (CTA) performed before the
dissection occurred and showing a normal sized aorta
(Fig. 3A, B).
Exclusion criteria were as follows:
 residual type B aneurysmal degeneration after repair of
type A aortic dissection
 thoraco-abdominal aneurysm caused by dissection
 dissection variants such as intramural haematoma and
penetrating aortic ulcer
 acute dissection caused by blunt traumatic injury.
Informed consent was signed by each patient; retro-
spective analysis of the anonymised data did not require
approval of the institutional review board. Each case was
collegially reviewed by the coordinators (GP, PO, ST), andFigure 3. Acute type B aortic dissection presenting with a total diamete
previous computed tomography angiography (CTA) showing a normalthe cases were merged into one multicentre database for
the retrospective analysis.Operative details
All TBAADs included in this cohort were diagnosed in the
hyperacute or acute phases by spiral or computed tomog-
raphy angiography, and immediately managed by best
medical treatment. TEVAR was performed in the operating
theatre, with general anaesthesia for all patients. Usually,
stent graft (SG) oversizing was 10% at most, according to
the diameter of the normal aorta in the proximal landing
zone, while at the planned distal landing zone (LZ) the sizing
was performed considering the overall aortic diameter
which included both the true (TL) and false lumen (FL). The
aim of the TEVAR was firstly to seal the proximal aortic
entry tear to abolish antegrade flow into the FL aneurysm,
and secondly to cover the entire descending thoracic aorta
to seal off the DTA. When 2 SGs were planned to be
implanted, the sequence of SG deployment was alwaysr <55 mm (B) but with >50% diameter increase compared with a
aortic sizing (A).
Figure 4. Follow-up CTA after TEVAR plus uncovered stent along the visceral segment for acute type B aortic dissection complicated by
aneurysm. False lumen thrombosis obtained along the thoracic endograft (class 1, according to Parsa et al.,6 A, B) and in the total
descending aorta (class 2, according to Parsa et al.,6 C, D).
796 G. Piffaretti et al.proximal first, and then distally. Balloon angioplasty of the
proximal and distal landing zones was not performed on a
routine basis. In those cases with planned intentional
coverage of the left subclavian artery (LSA), adjunctive
prophylactic revascularisation was performed in selected
cases (e.g. in stable haemodynamic conditions, when aortic
coverage was 20 cm, when the patient had a previous
abdominal aortic aneurysm repair, in those whose coronary
circulation was supplied by the left internal mammary, in
the presence of a hypoplastic contralateral vertebral artery,
left handed professionals, and left arm arteriovenous fistula
for dialysis). Cerebrospinal fluid drainage was not per-
formed on a routine basis but selectively (spinal cord
bleeding risk from ongoing anticoagulant or antiplatelet
therapy, when thoracic aortic coverage was 20 cm with
previous/synchronous abdominal aortic aneurysm repair,
and/or LSA coverage).18,19 Graft materials and manufac-
turers are reported in Appendix I.
Aortic assessment and follow-up
After intervention, the follow-up imaging protocol included
triple phase spiral/CTA performed at 1, 6, and 12 months
post-operatively, and on an annual basis thereafter. Atten-
tion was focused on the sealing zones, FL thrombotic status,
and aortic measurements. Computed tomography scans
were reviewed by vascular surgeons and interventionalradiologists. False lumen patency was defined by the
presence of contrast within the FL on the arterial or venous
phase of the CTA. The short axis diameter of the TL, FL, and
total aorta was quantified on the pre-operative and the
most recent post-operative CTA at different levels (distal
aortic arch just below the LSA take off, at the bifurcation of
the left and right pulmonary arteries, the diaphragmatic
aortic hiatus, and the infrarenal aorta). Aortic diameter was
measured adventitia to adventitia; the estimation of the TL/
FL ratio before and after TEVAR was measured just below
the LSA, and at the distal edge of the SG.
Definition
Type B aortic dissection was classified according to identi-
fication of the clinical symptom onset: hyperacute (0e
24 hours), acute (2e7 days), subacute (8e30 days), and
chronic (30 days).20 Comorbidities were defined according
to the Society of Thoracic Surgeons adult database.21
Morphological characteristics and outcomes were defined
according to the European Association for Cardiothoracic
Surgery/European Society for Cardiovascular Surgery
(EACTS/ESCVS) best practice guidelines for reporting treat-
ment results in the thoracic aorta, and/or the Society for
Vascular Surgery (SVS) ad hoc committee on TEVAR
reporting standards.22,23 Primary technical success was
defined as coverage of the proximal entry tear in the









Obesity (BMI >30) 5 (22.7)
Ischaemic heart disease 3 (13.6)
Diabetes 3 (13.6)




EuroSCORE II, (mean  SD) 23  18 (IQR 13e25)
M ¼ male; F ¼ female; COPD ¼ chronic obstructive pulmonary
disease; BMI ¼ body mass index; GFR ¼ glomerular filtration rate.
a Non-dissection surgery.
TEVAR for Acute Dissecting Type B Aneurysm 797absence of surgical conversion to open repair or death
24 hours. Follow-Up Index (FUI) described follow-up
completeness at the given study end date as the ratio be-
tween the investigated and the potential follow-up pe-
riods.24 TEVAR related mortality included deaths as a result
of aneurysm rupture, surgical conversion, or complications
of TEVAR unsolved by additional procedures. Favourable
aortic remodelling was defined as FL thrombosis in the
whole descending thoracic segment or longer, and/or an
aneurysm diameter reduction of at least 5 mm. False lumen
thrombosis was defined according to Parsa et al.6: class 0,
designates some retrograde FL perfusion along the SG; class
1, designates thrombosis along the length of SG; class 2,
designates thrombosis of FL throughout the thoracic aorta
(Figs. 4A, 1, 2); class 3, designates complete thrombosis of
FL throughout the entire native aorta (Figs. 4B, 1, 2). The
analysis here evaluated early and long-term survival,
freedom from aortic related mortality (ARM), and freedom
from re-intervention.Table 2. Operative data.
Variable n (%)
Operative data
General anaesthesia 22 (100)





Aortic coverage, (cm  SD)
<20 4 (18.2)
20 18 (81.8)
Intervention (min  SD) 192  142
Blood loss (median, mL) 265
Contrast (median, mL) 150
PRBC (median, units) 1
Stent graft, (manufacturer)
Free-flo 8 (30.8)
Diameter (mm  SD) 37  3
Open adjunctive procedures
Carotid-subclavian by-pass 6










PRBC ¼ packed red blood cell; LSA ¼ left subclavian artery;
PETTICOAT, Provisional Extension to Induce Complete Attachment;
SMA ¼ superior mesenteric artery; RRA ¼ right renal artery
LCIA ¼ left common iliac artery; EVAR ¼ endovascular abdominal
aortic repair.Statistical analysis
Clinical data were prospectively recorded and tabulated in
Microsoft Excel (Microsoft Corp, Redmond, WA, USA): sta-
tistical analysis was performed with SPSS, release 23.0 for
Windows (IBM SPSS Inc.; Chicago, IL, USA). Categorical
variables were presented as frequencies and percentages,
continuous variables as mean  standard deviation (SD)
and interquartile (IQR) range; otherwise medians with
range were applied. Wilcoxon’s signed-rank test was used to
evaluate the difference in TL/FL ratio before and after
TEVAR. A p value < .05 was considered to be significant.
Cumulative survival, freedom from ARM and freedom from
re-intervention rates were estimated using the Kaplan-
Meier method with 95% confidence interval (CI).
RESULTS
Cohort data
Twenty-two patients were treated, representing 16% of the
179 type B acute aortic dissections observed during the
study period, of which 41.5% presented with complications
in the hyperacute or acute periods. Connective tissue dis-
order related DTA was not observed. Demographic data and
risk factors are presented in Table 1. All the patients were
symptomatic with thoracic pain at presentation; malperfu-
sion was additionally present in two patients (9%), while
refractory/recurrent pain was observed in 10 (45.4%). The
pre-operative mean total aortic diameter was 66  26 mm
(range 42e130; IQR 51e64). Thrombus in the FL was never
observed on admission. Free rupture with haemothorax
was present in three (14%) patients. Dissection was limited
to the descending thoracic aorta in seven (32%) patients,
but involved the thoraco-abdominal aorta in 15 (68%).Operative details
Operative details are reported in Table 2. Urgent (<24 h)
intervention was performed in 12 (54.5%) patients: the restwere treated after a mean of 11  4 days (range 7e16; IQR
11e14). Mean aortic length coverage was 22  6 cm (range
10e35; IQR 20e25). Cerebrospinal fluid drainage was used
in 5 (23%) patients. All patients were admitted to the
Table 3. Post-operative complication (SVS grading scorea).
Complicationa n (%) Treatment
Mild
Acute kidney injury 2 Conservative
Atrial fibrillation 1 Amiodarone
Acute lung injury 2 C-PAP
Paraparesis 1 KT
Severe
Acute mesenteric ischaemia 2 Hartman (1);
AMS stent (1)
Acute lung injury 1 OTI
Cardiogenic shock 1 Sudden death
KT¼ kinesiotherapy; SMA¼ left subclavian artery; SMA¼ superior
mesenteric artery OTI ¼ orotracheal intubation.
a See Fillinger et al. (2010).23
Figure 5. Kaplan-Meier estimates of major aortic outcomes: overall
798 G. Piffaretti et al.intensive care unit with a median length of stay of 4 days
(range 1e33; IQR 1e4).survival, aortic related mortality, and freedom from aortic re-
intervention.









6 Open repair Dead




SINE ¼ stent graft induced new entry site; TAAA ¼ thoraco-
abdominal aortic aneurysm; TEVAR ¼ thoracic endovascular
aortic repair; LSA, left subclavian artery; FL, false lumen FEVAR,Early results
Primary technical success was 91% (n ¼ 20/22): primary
conversion was never performed. In hospital TEVAR related
mortality was 14% (n ¼ 3): causes of death included
cardiogenic shock (n ¼ 1; no aortic rupture), mesenteric
ischaemia (n ¼ 1, visceral malperfusion at admission), and
multiple organ failure (n ¼ 1). Spinal cord ischaemia
occurred in 1 (4.5%) patient (non-disabling paraparesis);
retrograde type A aortic dissection (RTAD) was not
observed. TEVAR related complications and their treat-
ments are reported in Table 3. Mean hospitalisation was
12  11 days (range 3e50; IQR 5e15): all patients who
survived were discharged home, without permanent or
definitive physical disability.fenestrated endovascular aortic repair.Late outcomes
All surviving patients were available for follow-up. The mean
follow-up was 56  45 months (range 6e149; IQR 12e82):
the mean FUI was 0.97  0.1. During follow-up the cu-
mulative mortality was 26.3%: five patients died after a
mean period of 34 months (range 6e84). During follow-up,
the TEVAR related mortality was 5% (n ¼ 1): this patient
died because of multiple organ failure after OR of a type IV
thoraco-abdominal aortic aneurysm. Further causes of
death included acute myocardial infarction (n ¼ 1), cancer
(n ¼ 1), chronic respiratory insufficiency (n ¼ 1), and sepsis
caused by pneumonia (n ¼ 1). Stent graft breakage,
migration, or infection was not seen. Kaplan-Meier estimate
of survival was 82% (95%CI: 61.5e93) at 1 year, and 64%
(95%CI: 41e82) at 5 year (Fig. 5). Seventeen (89%) patients
had CTA at 1 year, 12 (63%) at 3 years, and seven (37%) at
5 years. Among follow-up CTA evaluations, aneurysm sac
enlargement was not observed, while 2 (10.5%) patients
had significant aneurysm diameter reduction. Seventeen
(89.5%) patients had class 2 thrombosis, but no patient
presented with class 3 FL thrombosis. The TL/FL ratio was
significantly improved after TEVAR just below the LSA origin
(0.7  0.2 vs. 0.9  0.1, p ¼ .002) and the distal edge of theSG (0.7  0.2 vs. 0.9  0.2, p ¼ .025). During the follow-up,
ongoing primary clinical success was 79%: four patients
required secondary aortic intervention (Table 4). Freedom
from ARM at 1 and 5 year was 86% (95%CI: 66e95), while
freedom from re-intervention was 95% (95%CI: 75.5e95) at
1 year, and 77% (95%CI: 50e92) at 5 year (Fig. 5).DISCUSSION
The main findings of this study are the prevalence of DTA as
a complication of TBAAD in the hyperacute or acute phases,
which is underreported in the literature, and the acceptable
early and late results of TEVAR as management, especially
when compared with OR.
In the hyperacute or acute phases, complicated TBAAD
has been defined by the presence of aortic rupture, major
organ malperfusion, or persistent symptoms despite best
medical treatment.1 Few series specifically mentioned DTA
5 cm as sudden complication of TBAAD on admission in
the early setting. Despite its prevalence being reported in
the range of 20e32%, the results of TEVAR for such con-
dition have not been specifically analysed.1,2,5e17,25 In our
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Xu et al.7 84 14  22 n.s.r. n.s.r. n.s.r. 1.2 0 4.5 1.2 33  19 n.s.r. 4.8 57.1 0 n.s.r. 3.6 84.4 @ 5y
Czerny et al.8 14 19 14.3 n.s.r. 19 0 n.s.r. n.s.r. 0 34 35.7 7.1 n.s.r. n.s.r. n.s.r. 7.1 n.s.r.
Oberhuber
et al.9
19 36 n.s.r. n.s.r. n.s.r. 0 5.2 0 0 13 5.2 47.3 77.7 0 n.s.r. n.s.r. n.s.r.
Kang et al.10 47 25 22 n.s.r. n.s.r. 5 0 2 3.9 24 39 22 n.s.r. n.s.r. n.s.r. n.s.r. 80 @ 3y
Mani et al.11 58 29  31 13.8 24.1 22  10 5.2 1.7 n.s.r. 6.9 38  28 38 21.8 50 n.s.r. 71 @ 3y 3.6 64 @ 3y
Nozdrzykowski
et al.12
32 3.2 18.8 n.s.r. n.s.r. 6.2 9.3 34.4 n.s.r. n.s.r. n.s.r. 28.1 n.s.r. n.s.r. n.s.r. n.s.r. 87.5 @ 3y
Scali et al.13 80 16 9 24 78.2 2.5 10 1.2 1.2 18 51 29 17.3 0 70 @ 3y 0 70 @ 5y
Leshnower
et al.14
31 47  44 33 39 22  4 0 0 0 0 21  20 80.6 19 66.6 n.s.r. 76.9 @ 5 n.s.r. 80 @ 5y
Hughes et al.15 32 32  44 n.s.r. n.s.r. 23  6 0 0 n.s.r. 6.3 54 84.4 21.8 80 0 n.s.r. 0 71.2 @ 6y
Nathan et al.16 47 54  50 71.4 57.4 78.7 4.3 6.4 6.4 0 31  18 85.2 20 88.8 11.1 54 @ 5y 2.2 89 @ 5y
van Bogerijen
et al.17
32 20  28 43.7 59.4 71.9 0 0 3.1 0 34.8 53.1 15.6 80 0 87.5 @ 3y n.s.r. 78.1 @ 5
Overall (mean) 43 27 28.2 44.6 76.2 2.2 3.2 6.4 1.9 30 52.5 21.5 64.7 1.8 3
DTA ¼ descending thoracic aneurysm; Pts ¼ patients; AD ¼ aneurysm onset from acute dissection; TAAD ¼ acute type A aortic dissection; AoCo ¼ aortic coverage, meaning extent of total
descending thoracic aortic coverage; Op M ¼ operative mortality; SCI ¼ spinal cord ischaemia; CVA ¼ cerebrovascular accident; AKI ¼ acute kidney injury; RTAD ¼ retrograde acute type A
aortic dissection; FLT ¼ false lumen thrombosis; SAI ¼ secondary aortic intervention; EVR ¼ endovascular repair; Redo M ¼ mortality of redo endovascular repair; FFR ¼ freedom from re-




















800 G. Piffaretti et al.experience, aortic dilatation was more common than other
types of complications at the clinical onset of TBAAD:
although it involved only 16% of all TBAADs, it represented
41.5% of the complication events and was the most
frequent indication for immediate operative repair.
Open repair for complicated TBAAD is associated with a
significant in hospital mortality rate, in the range of 11.5e
29.3%.1,2,5 Large data set analysis showed that TEVAR for
thoracic aortic dissection is associated with a significantly
lower mortality rate and a greater number of patients dis-
charged home.3 In our series, TEVAR related mortality was
14%: this is a higher rate than the average 2.2% reported in
the literature summary (Table 5), but lower than the 23%
predicted mortality for OR.26 Moreover, almost all series in
the literature analysed a mixed cohort of dissecting aneu-
rysms, and did not specify which of the cases were TBAAD
complicated by DTA since the beginning of clinical onset.
Promoting thrombosis of the FL and aortic remodelling
are recognised benefits of TEVAR when treating
TBAAD.3,4,14,15 Recently, data from the ADSORB trial
showed significantly better remodelling at 1 year induced
by the best medical treatment plus SG in the acute setting:
in particular, 57% FL thrombosis, 63% of freedom from
aortic dilatation, and no rupture.27 Although our cohort
represents a different clinical setting, and specific volu-
metric analysis was not performed, in this challenging
context TEVAR yielded similar positive results, such as the
cumulative 89.5% FL thrombosis rate, a significant
improvement in the TL/FL ratio, and the absence of thoracic
aortic enlargement. This satisfactory outcome could be
explained by the combination of variables, such as effective
abolition of the antegrade flow induced by the proximal
aortic entry tear closure, the smoothness and plasticity of
the lamella that may be completely remodelled, and the
absence of FL thrombosis at presentation.
Secondary aortic interventions have commonly been
described in TEVAR series reporting on TBAADs, usually
with a higher prevalence compared with re-intervention
after OR.6e17 Nevertheless, 65% of re-interventions identi-
fied in the present literature summary were managed
endovascularly, and the redo related mortality was lower
than the mortality rate of the first intervention. In the
present series, the cumulative 79% freedom from aortic re-
intervention rate is similar to the mean rate noted in the
literature summary. Furthermore, secondary aortic in-
terventions were performed predominantly with endovas-
cular SG, and ARM was only associated with the need of
open conversion (graft replacement of a type IV TAAA).
Although the estimated overall survival was as low at
64% at 5 years in our series, the estimated ARM was 86%,
which is in line with the 70e89% survival range at 5 years
reported in the literature summary. A clear explanation for
the worse survival of patients with a TBAAD and a dilatation
at admission is difficult to find. Firstly, our cohort included
only TBAAD treated in the urgent setting because of a
complication of the disease in the acute phase, which de-
scribes a higher-risk cohort, while the literature summary
reported only subacute and/or chronic patients. Secondly,the high operative risk of this cohort does not find mean-
ingful comparison because the literature lacks references to
specific operative risk stratification, or homogeneity in the
follow-up period. In addition, differences could be related
to the high follow-up compliance (>60% at 3 years had
follow-up CTA), which was an issue described in other ex-
periences.10,11,13,16 Lastly, the present data reflect strict
observation of the outcome definitions, which is often not
present or reported heterogeneously in other series.16
Future studies comparing TEVAR results in TBAAD with
and without DTA/significant aortic enlargement will be
useful to better define the risk profile and the mid-/long-
term outcome of such cohorts.Limitations
The present study has clear limitations. First, it was a
retrospective study with sampling bias: neither medical
therapy alone nor OR arms were included for comparison.
Multivariate analysis would have been misleading with this
cohort size and thus was not performed. Consequently,
results may be underpowered to demonstrate meaningful
associations between pre-operative predictors and post-
operative outcomes. Lastly, no volumetric analysis was
performed, which may have offered a more comprehensive
and precise assessment of aortic remodelling for dissection
related pathology. Despite these limitations, inclusion
criteria resulted in a homogeneous cohort in terms of
epidemiological and demographic data. Follow-up was
performed at approximately 5 years and included clinical
visits and radiological examinations. Outcomes adhered
systematically to the proposed guidelines, which compare
well with those of other studies.
CONCLUSION
In our experience, DTA is a frequent complication from the
very beginning of the clinical onset of TBAAD. In this high-
risk cohort of patients, TEVAR showed satisfactory results,
better than those predicted by the risk score for OR, with
favourable stability of the aortic diameter and no aortic
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